Announced Fri, 3 Jul · 17:35 IST
US FDA inspection at Pithampur facility ends with 2 procedural observations
Business Updates View source PDF
RUBICON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+5.5%1-day move
₹1312.10
prior close
₹1330.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.1+2.1+3.2+3.8+5.5+6.8+7.3+9.0+9.7+10.6+20.0———
Up moveDown movePending
AI summary
US FDA inspected Rubicon Research's Pithampur facility from June 29 to July 3, 2026, the first inspection since its acquisition last year. A Form 483 with 2 procedural observations was issued, none related to data integrity. The company plans to address these with the regulator and remains on track to start commercial operations at the facility from Q1 calendar year 2027.
Likely market impact
Mildly positive - only 2 procedural observations, no data integrity issues, and company is confident of addressing them. Supports planned Q1 2027 ramp-up.